CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5056-5062

  Hirata, Hiroshi ^a   Hinoda, Yuji ^b   Kikuno, Nobuyuki ^a   Kawamoto, Ken ^a   Dahiya, Angela V ^a   Suehiro, Yutaka ^b   Tanaka, Yuichiro ^a   Dahiya, Rajvir ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 G801A; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ALPHA CHEMOKINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; CODON; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; CHEMOKINES, CXC; CODON; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 34548824078     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0859     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;50:8-29.
2. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schroder FH. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol 2006;175:1332-6.
3. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803.
4. Chan JM, Holick CN, Leitzmann MF, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006;17:199-208.
5. Shukla S, Gupta S. Dietary agents in the chemoprevention of prostate cancer. Nutr Cancer 2005;53:18-32.
6. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001;91:66-73.
7. Mochizuki H, Matsubara A, Teishima J, et al. Interaction of ligand-receptor system between stromal-cell - derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 2004;320:656-63.
8. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
9. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-73.
10. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998;279:389-93.
11. Watanabe MA, de Oliveia Cavassin GG, Orellana MD, et al. SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1 infected individuals. Microb Pathog 2003;35:31-4.
12. Dommange F, Cartron G, Espanel C, et al. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J 2006;20:1913-5.
13. Mehta SA, Christopherson KW, Bhat-Nakshatri P, et al. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene 2007;26:3329-37.
14. Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 2006;66:10671-6.
15. Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006;98:911-9.
16. Santos AM, Sousa H, Pinto D, et al. Linking P53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer. Eur J Cancer 2006;42:958-63.
17. Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-61.
18. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
19. Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res 1990;18:4961.
20. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of α(v)β(3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007;67:61-73.
21. Razmkhah M, Doroudchi M, Ghayumi SM, Erfani N, Ghaderi A. Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer 2005;49:311-5.
22. Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T, Ghaderi A. Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett 2005;225:261-6.
23. Dimberg J, Hugander A, Lofgren S, Wagsater D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med 2007;19:11-5.
24. Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-2.
25. Singh S, Singh UP, Grizzle WE, Lillard JW, Jr. CXCL12-4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004;84:1666-76.
26. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-7.
27. Cooper CR, Chay CH, Gendernalik JD, et al. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer 2003;97:739-47.
28. Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006;66:32-48.
29. Oakley-Girvan I, Feldman D, Eccleshall TR, et al. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 2004;13:1325-30.
30. Vijayalakshmi K, Vettriselvi V, Krishnan M, Shroff S, Jayanth VR, Paul SF. Cytochrome p4501A1 gene variants as susceptibility marker for prostate cancer. Cancer Epidemiol Biomarkers Prev 2005;1:251-8.